Kincaid E H, Miller P R, Meredith J W, Chang M C
Department of General Surgery, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27157, USA.
Shock. 1998 Feb;9(2):79-83. doi: 10.1097/00024382-199802000-00001.
Inadequate splanchnic perfusion, detected as a low gastric intramucosal pH (pHi), in the face of normal systemic perfusion predicts an increased risk for multiple organ failure after trauma. Although the exact etiology of this low pHi is unknown, angiotensin II is thought to be an important regulator of gut perfusion during and after resuscitation from shock. The purpose of this study is to determine whether enalaprilat, an angiotensin-converting enzyme inhibitor, improves gut perfusion in critically injured patients. To test this hypothesis, 18 trauma patients monitored with a nasogastric tonometer and a pulmonary artery catheter were enrolled in a prospective study. A single dose of enalaprilat, .625 mg, was given as an i.v. bolus or a 4 h infusion following systemic resuscitation. Pre- and postdrug tonometric and hemodynamic data, including cardiac index, mean arterial pressure, right ventricular end-diastolic volume index, systemic vascular resistance index, and oxygen transport variables were compared using the paired t test. Results demonstrate that pHi was significantly improved after 4 h (7.13 +/- .04 to 7.19 +/- .03, p = .03) and after 24 h compared with baseline (7.14 +/- .04 to 7.25 +/- .04, p = .04). Overall, pHi increased in 12 of 18 patients. No significant differences were observed in any of the studied hemodynamic or systemic perfusion variables including mean arterial pressure (92 +/- 4 to 87 +/- 4, p = .24) and oxygen delivery (669 +/- 33 to 675 +/- 32, p = .82). In examining the determinants of pHi, the intramucosal-arterial PCO2 difference was improved after enalaprilat administration (27 +/- 6 to 17 +/- 3 mmHg, p = .04) while no difference was observed in arterial bicarbonate (19.5 +/- .7 to 19.7 +/- .8, p = .90). Additionally, the change in pHi observed with enalaprilat correlated with predrug intramucosal-arterial PCO2 difference (r = .74, r2 = .55, p = .0005). These results demonstrate that enalaprilat improves gut perfusion as measured by gastric tonometry in critically injured patients, and that this effect appears to be independent of changes in systemic perfusion.
在内脏灌注不足(表现为胃黏膜内pH值(pHi)降低)而全身灌注正常的情况下,创伤后多器官功能衰竭的风险会增加。尽管这种低pHi的确切病因尚不清楚,但血管紧张素II被认为是休克复苏期间及复苏后肠道灌注的重要调节因子。本研究的目的是确定血管紧张素转换酶抑制剂依那普利拉是否能改善重症创伤患者的肠道灌注。为验证这一假设,18例使用鼻胃张力计和肺动脉导管进行监测的创伤患者被纳入一项前瞻性研究。在全身复苏后,静脉推注或4小时输注单剂量的依那普利拉,剂量为0.625毫克。使用配对t检验比较用药前后的张力测量和血流动力学数据,包括心脏指数、平均动脉压、右心室舒张末期容积指数、全身血管阻力指数和氧输送变量。结果显示,4小时后(从7.13±0.04升至7.19±0.03,p = 0.03)以及24小时后与基线相比(从7.14±0.04升至7.25±0.04,p = 0.04),pHi均显著改善。总体而言,18例患者中有12例pHi升高。在所研究的任何血流动力学或全身灌注变量中均未观察到显著差异,包括平均动脉压(从92±4降至87±4,p = 0.24)和氧输送(从669±33升至675±32,p = 0.82)。在研究pHi的决定因素时,依那普利拉给药后黏膜内 - 动脉血二氧化碳分压差有所改善(从27±6降至17±3 mmHg,p = 0.04),而动脉血碳酸氢盐无差异(从19.5±0.7升至19.7±0.8,p = 0.90)。此外,依那普利拉引起的pHi变化与用药前黏膜内 - 动脉血二氧化碳分压差相关(r = 0.74,r2 = 0.55,p = 0.0005)。这些结果表明,依那普利拉可改善重症创伤患者通过胃张力测量法测得的肠道灌注,且这种作用似乎与全身灌注的变化无关。